This is a working overview of dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-13. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
=== 1991 state attorney general race === In 1991, Kennedy ran for Louisiana attorney general to succeed the retiring William J. Guste. At 39, he was the youngest candidate in the race. In the state's jungle primary he received 288,382 votes (20%), placing third behind Ben Bagert, who received 313,143 (22%), and Richard Ieyoub, who received 447,457 (31%).
=== Myomesin 3 === Myomesin 3 is the least researched in the myomesin class due to it being the most recently discovered. It is encoded by the MYOM3 gene. It is located in the M6/M6' lines of the M-band and is expressed in intermediate skeletal muscles and adult cardiac muscles (specifically in the left ventricle and left atrium). MYOM3 is especially expressed in neonatal skeletal muscles, extraocular muscles, slow muscles, and IIA skeletal fibers. Myomesin 3 is the only member of the myomesin protein family to be completely absent from cardiac expression. Myomesin 3 displays an inverse relationship with myomesin 2.
== Structure == The outer shell of the long bone is made of cortical bone also known as compact bone. This is covered by a membrane of connective tissue called the periosteum. Beneath the cortical bone layer is a layer of spongy cancellous bone. Inside this is the medullary cavity which has an inner core of bone marrow, it contains nutrients and help in formation of cells, made up of yellow marrow in the adult and red marrow in the child.
== Career == Daly worked as a physical science instructor at Howard University, from 1947 to 1948 while simultaneously conducting research under the direction of Herman Branson. After being awarded an American Cancer Society grant to support her postdoctoral research, she joined Alfred E. Mirsky's group at the Rockefeller Institute, which studied the cell nucleus and its constituents. This was the start of a seven-year research program at the Rockefeller Institute of Medicine, where Daly examined how proteins are constructed in the body. At the time, the structure and function of DNA were not yet understood. Daly began working in the College of Physicians and Surgeons at Columbia University in 1955. In collaboration with Quentin B. Deming, she studied arterial metabolism. She continued this work as an assistant professor of biochemistry and of medicine at the Albert Einstein College of Medicine at Yeshiva University, where she and Deming moved in 1960. From 1958 to 1963, she also served as an investigator for the American Heart Association. During her final years at Albert Einstein College, per Daly's efforts to increase minority enrollment in professional and graduate schools, she helped run the Martin Luther King -Robert F. Kennedy program to help prepare black students for admission. In 1971 she was promoted to associate professor. In 1975, Daly was one of 30 minority women scientists to attend a conference examining the challenges facing minority women in STEM fields. The conference was held by the American Association for the Advancement of Science.
Sources: en.wikipedia.org
The δ13C and δ34S of coexisting carbonate minerals and sulfides can be used to determine the pH and oxygen fugacity of the ore-bearing fluid during ore formation. Scientists measure the sulfur isotopes of minerals in rocks and sediments to study the redox conditions in past oceans. Sulfate-reducing bacteria in marine sediment fractionate sulfur isotopes as they take in sulfate and produce sulfide. Prior to the 2010s, it was thought that sulfate reduction could fractionate sulfur isotopes up to 46 permil and fractionation larger than 46 permil recorded in sediments must be due to disproportionation of sulfur compounds in the sediment. This view has changed since the 2010s as experiments showed that sulfate-reducing bacteria can fractionate to 66 permil. As substrates for disproportionation are limited by the product of sulfate reduction, the isotopic effect of disproportionation should be less than 16 permil in most sedimentary settings. In forest ecosystems, sulfate is derived mostly from the atmosphere; weathering of ore minerals and evaporites contribute some sulfur. Sulfur with a distinctive isotopic composition has been used to identify pollution sources, and enriched sulfur has been added as a tracer in hydrologic studies. Differences in the natural abundances can be used in systems where there is sufficient variation in the 34S of ecosystem components. Rocky Mountain lakes thought to be dominated by atmospheric sources of sulfate have been found to have measurably different 34S values than lakes believed to be dominated by watershed sources of sulfate.
Early on the morning of September 11, 2001, nineteen hijackers took control of four commercial airliners (two Boeing 757s and two Boeing 767s). Large planes with long flights were selected for hijacking because they would have more fuel. Nobody on the planes survived.
== B == BET – BET surface area measurement (BET from Brunauer, Emmett, Teller) BiFC – Bimolecular fluorescence complementation BKD – Backscatter Kikuchi diffraction, see EBSD BRET – Bioluminescence resonance energy transfer BSED – Back scattered electron diffraction, see EBSD
== Side effects == The effects of local skin reactions with clascoterone were similar to placebo in two large phase III randomized controlled trials. Suppression of the hypothalamic–pituitary–adrenal axis (HPA axis) may occur during clascoterone therapy in some individuals due to its cortexolone metabolite. HPA axis suppression as measured by the cosyntropin stimulation test was observed to occur in 3 of 42 (7%) of adolescents and adults using clascoterone for acne. HPA axis function returned to normal within 4 weeks following discontinuation of clascoterone. Hyperkalemia (elevated potassium levels) occurred in 5% of clascoterone-treated individuals and 4% of placebo-treated individuals.
Artistic Achievement – Ori and the Blind Forest Audio Achievement – Everybody's Gone to the Rapture Best Game – Fallout 4 British Game – Batman: Arkham Knight Debut Game – Her Story Family – Rocket League Game Design – Bloodborne Game Innovation – Her Story Mobile & Handheld – Her Story Multiplayer – Rocket League Music - Everybody's Gone to the Rapture Original Property – Until Dawn Performer – Merle Dandridge (as Kate Collins, Everybody's Gone to the Rapture) Persistent Game – Prison Architect Sports – Rocket League Story – Life Is Strange Special - Amy Hennig BAFTA Ones to Watch Award – Sundown Academy Fellowship – John Carmack AMD eSports Audience Award – Smite
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.